P. C. Nowell, D. Hungerford, Y. Ben-neriah, Q. G. Daley, A. M. Mes-mason et al., The chronic myelogenous leukemia-specific p210 protein is the product of the bcr-abl hybrid gene, Science, vol.132, p.212, 1960.

G. Q. Daley, R. A. Van-etten, D. Baltimore, A. C. Eaves, J. D. Cashman et al., Unregulated proliferation of primitive chronic myelogenous leukemia progenitors in the presence of normal marrow adherent cells, Proc Natl Acad Sci, vol.247, p.824, 1986.

P. Stryckmans, L. Debussher, and M. Socquet, Regulation of bone marrow myeloblast proliferation in chronic myeloid leukemia, Cancer Res, vol.36, 1976.

E. Spooncer, L. Fairbairn, G. J. Cowling, T. M. Dexter, A. D. Whetton et al., Biological consequences of p160v-abl protein tyrosine kinase activity in a primitive, multipotent hematopoietic cell line, Leukemia, vol.8, p.620, 1994.

R. S. Chapman, A. D. Whetton, and C. Dive, The suppression of druginduced apoptosis by activation of v-abl protein tyrosine kinase, Cancer Res, vol.54, 1994.

A. Bedi, B. A. Zehnbauer, J. P. Barber, S. J. Sharkis, and R. J. Jones, Inhibition of apoptosis by BCR-ABL in chronic myelogenous leukemia, Blood, vol.83, p.2038, 1994.

A. Bedi, J. P. Berber, G. C. Bedi, W. S. El-deiry, D. Sidransky et al., BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents, Blood, vol.86, p.1179, 1994.

P. Laneuville, M. Timm, and A. T. Hudson, Bcr/abl expression in 32D c13(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors, Cancer Res, vol.54, p.1360, 1994.

A. J. Mcgahon, W. K. Nishioka, S. J. Martin, A. Mahboubi, T. G. Cotter et al., Regulation of the Fas apoptotic cell death pathway by Abl, J Biol Chem, vol.270, p.22625, 1995.

T. Witte, E. J. Mensink, C. A. Evans, J. M. Lord, P. J. Owen-lynch et al., Suppression of apoptosis by v-ABL protein tyrosine kinase is associated with nuclear translocation and activation of protein kinase C in an interleukin-3-dependent haematopoietic cell line, J Cell Sci, vol.8, p.2591, 1995.

O. Kan, S. A. Baldwin, and A. D. Whetton, Apoptosis is regulated by the rate of glucose transport in an interleukin 3 dependent cell line, J Exp Med, vol.180, 1994.

D. Cortez, G. Stoica, J. H. Pierce, and A. M. Pendergast, AD: V-Abl-mediated apoptotic suppression is associated with SHC phosphorylation without concomitant mitogen-activated protein kinase activation, J Biol Chem, vol.13, p.2589, 1995.

E. S. Alnemri, D. J. Livingston, D. W. Nicholson, G. Salvesen, N. A. Thornberry et al., Human ICE/CED-3 protease nomenclature, Cell, vol.87, p.171, 1996.

T. Patel, G. J. Gores, and S. H. Kaufmann, The role of proteases during apoptosis, FASEB J, vol.10, 1996.

K. Kuida, J. A. Lippke, G. Ku, M. W. Harding, D. J. Livingston et al., The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors, mice deficient in interleukin-1?-converting enzyme, vol.267, p.1113, 1995.

E. Solary, R. Bertrand, K. Kohn, Y. Pommier, P. K. Smith et al., Differential induction of apoptosis in undifferentiated and differentiated HL60 cells by DNA topoisomerase I and II inhibitors, Nucleic Acids Res, vol.81, p.1215, 1985.

J. Schlegel, I. Peters, S. Orrenius, D. K. Miller, N. A. Thornberry et al., Bcl-2 modulation of apoptosis induced by anticancer drugs: Resistance to thymidilate stress is independent of classical resistance pathways, J Cell Biochem, vol.271, p.33, 1992.

J. Lotem, L. Sachs, M. Enari, R. V. Talanian, W. W. Wong et al., Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor ?1 and cancer chemotherapy compounds in myeloid leukemic cells, Nature, vol.80, p.1750, 1992.

Y. Gu, C. Sarnecki, R. A. Aldape, D. J. Livingston, M. Su et al., Cleavage of Poly(ADP-ribose)polymerase by interleukin-1? converting enzyme and its homologs Tx and Nedd-2, J Biol Chem, vol.32, p.446, 1995.

T. Skorski, M. Nieborowska-skorska, C. Barletta, L. Malaguarnera, C. Szczylik et al., Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligonucleotides combined with mafosfamide, J Clin Invest, vol.92, 1993.